Advertisement

Indian Journal of Gastroenterology

, Volume 37, Issue 6, pp 520–525 | Cite as

Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability

  • Juferdy KurniawanEmail author
  • Rino Alvani Gani
  • Irsan Hasan
  • Andri Sanityoso Sulaiman
  • Cosmas Rinaldi A. Lesmana
  • Chynthia Olivia Maurine Jasirwan
  • Kemal Fariz Kalista
  • Saut Horas Hatoguan Nababan
  • Steven Zulkifly
Original Article
  • 17 Downloads

Abstract

Introduction

Sofosbuvir (SOF) and daclatasvir (DCV) regimens are recommended for all genotypes of hepatitis C virus (HCV) infection. However, DCV accessibility is still low in several low– and middle-income countries. Ribavirin (RBV) is more affordable and has been known for chronic HCV treatment along with SOF or interferon. The aim of this study was to assess the efficacy of SOF + RBV and SOF + DCV regimens for treatment of chronic HCV in Indonesia.

Methods

We conducted a retrospective study among patients with chronic HCV who were treated with SOF. Data on SOV + RBV were collected from 2015 to 2016, while those on SOF + DCV were collected from 2016 to 2017. The baseline characteristics were recorded from the medical record unit in Cipto Mangunkusumo General Hospital, Jakarta, Indonesia. The primary outcome was the achievement of sustained virological response at 12 weeks (SVR12).

Results

Of 309 patients, 64.4% (199/309) had genotype 1 infections, 29.8% (92/309) had cirrhosis, and 4.9% (15/309) had co-infection with human immunodeficiency virus (HIV). At the end of treatment (EOT), 99.3% (136/137) patients in the SOF + RBV group and 99.4% (164/165) in SOF + DCV group had no detectable viral load. The criterion for SVR12 was met in 90.8% (109/120) patients in SOF + RBV regimen and 98.2% (108/110) in SOF + DCV regimen. Among patients with cirrhosis, 84.4% (38/45) patients and 100% (27/27) achieved SVR12 in the SOF + RBV and SOF + DCV groups, respectively.

Conclusion

SOF + DCV regimen had higher SVR rates compared to SOF + RBV regimen (p = 0.034). However, both the regimens showed an impressive outcome, with overall SVR12 rates above 90%, irrespective of presence of cirrhosis and HCV genotype. In non-structural protein 5A inhibitor limited setting, SOF + RBV regimen still can be used as treatment for HCV infection, particularly in non-cirrhotic patients.

Keywords

Daclatasvir Hepatitis C Ribavirin Sofosbuvir 

Notes

Compliance with ethical standards

Conflict of interest

JK, RAG, IH, ASS, CRAL, COMJ, KFK, SHHN, and SZ declare that they have no conflict of interest.

Ethics statement

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Disclaimer

The authors are solely responsible for the data and the content of the paper. In no way the Honorary Editor-in-Chief, Editorial Board Members, or the printer/publishers are responsible for the results/findings and content of this article.

References

  1. 1.
    World Health Organization. Global hepatitis report 2017. Geneva: World Health Organization; 2017.Google Scholar
  2. 2.
    Muljono DH. Epidemiology of hepatitis B and C in Republic of Indonesia. Euroasian J Hepatogastroenterol. 2017;7:55–9.CrossRefGoogle Scholar
  3. 3.
    Utama A, Tania NP, Dhenni R, et al. Genotype diversity of hepatitis C virus (HCV) in HCV-associated liver disease patients in Indonesia. Liver Int. 2010;30:1152–60.CrossRefGoogle Scholar
  4. 4.
    Akbar N, Sulaiman A, Gani RA, et al. Efficacy and safety of in-Asia-manufactured interferon alpha-2b in combination with ribavirin for therapy of naïve chronic hepatitis C patients: a multicenter, prospective, open-label trial. Indones J Gastroenterol Hepatol Dig Endosc. 2009;10:7–13.Google Scholar
  5. 5.
    European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–94.CrossRefGoogle Scholar
  6. 6.
    Bhatia HK, Singh H, Grewal N, Natt NK. Sofosbuvir: a novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacother. 2014;5:278–84.CrossRefGoogle Scholar
  7. 7.
    Te HS, Randall G, Jensen DM. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol (NY). 2007;3:218–25.Google Scholar
  8. 8.
    Lee C. Daclatasvir: potential role in hepatitis C. Drug Des Devel Ther. 2013;7:1223–33.CrossRefGoogle Scholar
  9. 9.
    World Health Organization. Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries. Geneva: World Health Organization; 2018.Google Scholar
  10. 10.
    Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10:702–26.CrossRefGoogle Scholar
  11. 11.
    Berden FA, Aaldering BR, Groenewoud H, IntHout J, Kievit W, Drenth JP. Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection: A systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2017;15:349–59.CrossRefGoogle Scholar
  12. 12.
    Osinusi A, Meissner EG, Lee YJ, et al. Efficacy of sofosbuvir and ribavirin for treatment of hepatitis C genotype-1 in an inner city population: virus and host factors that predict relapse: a randomized controlled trial. JAMA. 2013;310:804–11.CrossRefGoogle Scholar
  13. 13.
    Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21:762–8.CrossRefGoogle Scholar
  14. 14.
    Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.CrossRefGoogle Scholar
  15. 15.
    Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol. 2015;62:1040–6.CrossRefGoogle Scholar
  16. 16.
    Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312:353–61.CrossRefGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2019

Authors and Affiliations

  • Juferdy Kurniawan
    • 1
    Email author
  • Rino Alvani Gani
    • 1
  • Irsan Hasan
    • 1
  • Andri Sanityoso Sulaiman
    • 1
  • Cosmas Rinaldi A. Lesmana
    • 1
  • Chynthia Olivia Maurine Jasirwan
    • 1
  • Kemal Fariz Kalista
    • 1
  • Saut Horas Hatoguan Nababan
    • 1
  • Steven Zulkifly
    • 1
  1. 1.Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine Universitas IndonesiaCipto Mangunkusumo National General HospitalJakartaIndonesia

Personalised recommendations